LL-37 Peptide: Inflammation, Immunity & Antimicrobial Research

Scientifically reviewed by
Dr. Ky H. Le, MD

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

What began as antimicrobial research has revealed a peptide with surprising versatility. LL-37, the only cathelicidin found in research applications, now attracts scientists studying immunity, tissue repair models, and cardiovascular signaling.

This positively charged antimicrobial peptide disrupts bacterial membranes while activating cellular signaling pathways. Research laboratories use LL-37 to investigate everything from infection resistance to tissue regeneration mechanisms.

Key Research Insights

• LL-37 is a cathelicidin peptide that shows activity against bacteria, viruses, and fungi in vitro through membrane disruption.
• The peptide activates cellular signaling pathways that control immune responses and tissue repair processes.
• Laboratory studies examine LL-37 in tissue repair, vessel formation, and cardiovascular signaling models.
• Studies examine LL-37 signaling in tumor cell lines, autoimmune models, and neural research models.

What is LL-37 Peptide?

LL-37 is the only cathelicidin antimicrobial peptide (AMP) and part of the cathelicidin family of host defense peptides (HDP). This 37-amino acid peptide is produced through proteolytic cleavage of cationic antimicrobial protein 18 (hCAP18) by proteinase 3.

Unlike traditional antimicrobials that target specific pathogens, LL-37 shows broad-spectrum activity against bacteria, viruses, and fungi in laboratory studies. Its research applications extend beyond antimicrobial effects to include immune modulation, angiogenesis, and wound healing mechanisms.

LL-37 carries a net positive charge of +6 and adopts an amphipathic helix structure, making it well suited to membrane interaction studies and cellular research applications.

How LL-37 Works

LL-37’s biological activity stems from its unique structural properties and receptor interactions.

Membrane Interaction Mechanisms

LL-37 operates through a carpet-like mechanism rather than traditional pore formation. The peptide acts in a detergent-like fashion to disrupt membrane integrity through electrostatic and hydrophobic interactions.

Studies show that LL-37 exhibits two distinct pathways depending on membrane composition[1]. With unsaturated phospholipids, it forms pores, while with saturated phospholipids, it creates helical-rich fibrous structures.

This dual mechanism allows LL-37 to target diverse bacterial membranes. The peptide can penetrate bacterial cells to interact with intracellular targets, including acyl carrier proteins.

Cellular Signaling Pathways

LL-37 influences cellular pathways through receptor-mediated mechanisms. The peptide interacts with formyl-peptide receptor FPR2 to induce cellular migration and activation responses.

Research teams have identified LL-37’s role in activating VEGFA-PI3K/AKT/mTOR signaling pathways. Laboratory studies show this activation promotes cellular proliferation, migration, and tube formation[2].

The peptide also influences NF-κB and MAP kinase signaling cascades. These pathways regulate inflammatory responses and cellular stress responses across different tissue types.

Research Areas for LL-37 Peptide

Antimicrobial peptide LL-37 has opened many avenues for research applications.

Antimicrobial Properties

Laboratory testing reveals LL-37’s broad-spectrum activity against both Gram-positive and Gram-negative bacteria. The peptide targets pathogens from Pseudomonas, Escherichia, Staphylococcus, and Enterococcus genera.

Key antimicrobial findings include:

• Membrane disruption through electrostatic interactions
• Intracellular target binding to acyl carrier proteins
• Resistance to serum inactivation under physiological conditions
• Concentration ranges vary by bacterial species

Research indicates LL-37 maintains antimicrobial activity even in serum conditions in vitro[3]. This stability makes it valuable for laboratory antimicrobial studies.

Immunity and Immune System Effects

LL-37 functions as a bridge between innate and adaptive immunity responses. The peptide exhibits both pro-inflammatory and anti-inflammatory properties depending on cellular context.

In dendritic cell studies, LL-37 suppresses mature cell function by reducing IL-6 and TNF-α release. Research shows the peptide decreases expression of HLA-DR, CD80, CD83, CD86, and CCR7[4].

For macrophage research, LL-37 directs polarization toward M1 pro-inflammatory phenotypes. The peptide downregulates IL-10 while upregulating IL-12p40 in laboratory models.

Chemotactic studies reveal LL-37 induces neutrophil and eosinophil migration through FPR2 activation. Laboratory data shows increased chemokine production including CXCL8 and MCP-1/CCL-2[5].

Tissue Repair Model Studies

LL-37 shows angiogenic properties through direct effects on endothelial cells. Research models show the peptide induces vessel growth with wheel spoke-like structures similar to basic fibroblast growth factor[6].

Wound healing research reveals these mechanisms:

• Keratinocyte migration through epidermal growth factor receptor activation
• TGF-β release from intestinal epithelial cells
• Increased cellular proliferation and migration rates
• Changes in granulation tissue formation

Studies in hyperglycemic wound models report changes in granulation tissue formation and bacterial colonization[7]. These effects are particularly pronounced in hyperglycemic laboratory conditions.

Cardiovascular Research

LL-37 shows protective effects in cardiovascular research models. Observational studies associate higher plasma LL-37 levels with fewer adverse cardiovascular events in clinical study populations[8].

Research findings include:

• Mortality data in post-myocardial infarction research models
• Decreased unscheduled revascularization rates
• Anti-hypertrophy effects through NF-κB signaling inhibition
• Cardiac dysfunction attenuation in preclinical models

Laboratory studies using CRAMP (mouse homolog) show decreased levels in heart failure models, and added CRAMP attenuated cardiac dysfunction in these models[9].

Metabolic Studies

LL-37 research reveals connections to metabolic regulation. Studies examine its links with metabolic markers such as insulin signaling and lipid profiles[10].

The peptide influences lipid metabolism through Toll-like receptor activation in adipose tissue research. This activation stimulates pro-inflammatory cytokine secretion and contributes to insulin signaling disruption in laboratory models.

Research teams have studied how LL-37 inhibits islet amyloid polypeptide (IAPP) aggregation in vitro. LL-37 binds IAPP with high affinity, blocking amyloid formation and reducing pancreatic β-cell damage in research protocols.

Current Research Developments

Research teams are investigating LL-37’s role in autoimmune disease mechanisms. Current studies characterize the peptide as a T-cell autoantigen in skin inflammation research[11].

Scientists are studying post-translational modifications including citrullination and carbamylation. Research shows these modifications link to neutrophil-dominated inflammation and become targets for T-cell responses[12].

Tumor cell line research shows tissue-specific effects, with LL-37 promoting growth in some lines and inhibiting it in others. Laboratory studies report antiproliferative activity of LL-37 in colon, gastric, hematologic, and oral squamous carcinoma cell lines[13].

Neurological research is investigating LL-37’s brain effects. Studies indicate the peptide may contribute to neurodegenerative processes through chloride intracellular channel 1 activation[14].

In Vitro Research Applications

Research laboratories can utilize LL-37 across multiple experimental applications. The peptide’s diverse biological activities make it valuable for studying cellular mechanisms and disease processes.

Research Application	Mechanism	Study Focus
Antimicrobial Testing	Membrane disruption and intracellular targeting	Bacterial resistance mechanisms, broad-spectrum activity
Angiogenesis Studies	VEGFA-PI3K/AKT/mTOR pathway activation	Vessel formation, endothelial cell behavior
Immune Cell Research	FPR2 receptor signaling and cytokine modulation	Cell migration, inflammatory responses
Wound Healing Models	Growth factor receptor activation and cell migration	Tissue repair mechanisms, cellular proliferation
Cardiovascular Research	NF-κB signaling and cardiac signaling pathways	Cardiac stress models, signaling mechanisms

Quick Review

Key Takeaway: LL-37 is a promising research tool with applications spanning antimicrobial studies to cardiovascular research, offering laboratories a well-characterized peptide for investigating diverse biological mechanisms and disease processes.

LL-37 research requires high-purity peptides with consistent biological activity. Laboratory protocols depend on research-grade compounds that maintain structural integrity across experimental conditions.

Third-party testing checks peptide purity and amino acid sequence for reproducible research results. USA-manufactured LL-37 provides supply chain reliability and quality control standards that support rigorous research protocols.

This content is for research and educational purposes only. LL-37 is for research use only.

---

---

References

1. K. E. Ridyard and J. Overhage, “The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent,” MDPI AG, May 2021. doi: 10.3390/antibiotics10060650. https://doi.org/10.3390/antibiotics10060650
2. Y. Yang, G. Wu, Y. Wang, Q. Mao, D. Zhang, and J. Wu, “LL37 promotes angiogenesis: a potential therapeutic strategy for lower limb ischemic diseases,” Frontiers Media SA, Apr. 2025. doi: 10.3389/fphar.2025.1587351. https://doi.org/10.3389/fphar.2025.1587351
3. Z. OREN, J. C. LERMAN, G. H. GUDMUNDSSON, B. AGERBERTH, and Y. SHAI, “Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity,” Portland Press Ltd., Jul. 1999. doi: 10.1042/bj3410501. https://doi.org/10.1042/bj3410501
4. B. Yang et al., “Significance of LL‐37 on Immunomodulation and Disease Outcome,” Wiley, Jan. 2020. doi: 10.1155/2020/8349712. https://doi.org/10.1155/2020/8349712
5. J. M. Kahlenberg and M. J. Kaplan, “Little Peptide, Big Effects: The Role of LL-37 in Inflammation and Autoimmune Disease,” Oxford University Press (OUP), Nov. 2013. doi: 10.4049/jimmunol.1302005. https://doi.org/10.4049/jimmunol.1302005
6. R. Koczulla et al., “An angiogenic role for the human peptide antibiotic LL-37/hCAP-18,” American Society for Clinical Investigation, Jun. 2003. doi: 10.1172/jci17545. https://doi.org/10.1172/jci17545
7. R. Shi et al., “Self‐assembly of PEG–PPS polymers and LL‐37 peptide nanomicelles improves the oxidative microenvironment and promotes angiogenesis to facilitate chronic wound healing,” Wiley, Nov. 2023. doi: 10.1002/btm2.10619. https://doi.org/10.1002/btm2.10619
8. H. Zhao et al., “High Human Antimicrobial Peptide LL-37 Level Predicts Lower Major Adverse Cardiovascular Events after an Acute ST-Segment Elevation Myocardial Infarction,” Japan Atherosclerosis Society, Oct. 2022. doi: 10.5551/jat.63221. https://doi.org/10.5551/jat.63221
9. Q. Zhou et al., “The anti-microbial peptide LL-37/CRAMP levels are associated with acute heart failure and can attenuate cardiac dysfunction in multiple preclinical models of heart failure,” Ivyspring International Publisher, 2020. doi: 10.7150/thno.46225. https://doi.org/10.7150/thno.46225
10. A. D. Popa et al., “Cathelicidin: Insights into Its Impact on Metabolic Syndrome and Chronic Inflammation,” MDPI AG, Dec. 2024. doi: 10.3390/metabo14120672. https://doi.org/10.3390/metabo14120672
11. R. Lande et al., “The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis,” Springer Science and Business Media LLC, Dec. 2014. doi: 10.1038/ncomms6621. https://doi.org/10.1038/ncomms6621
12. R. Lande et al., “The nature of the post-translational modifications of the autoantigen LL37 influences the autoreactive T-helper cell phenotype in psoriasis,” Frontiers Media SA, Apr. 2025. doi: 10.3389/fimmu.2025.1546422. https://doi.org/10.3389/fimmu.2025.1546422
13. F. Lu, Y. Zhu, G. Zhang, and Z. Liu, “Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy,” Frontiers Media SA, Aug. 2022. doi: 10.3389/fphar.2022.944147. https://doi.org/10.3389/fphar.2022.944147
14. X. Chen et al., “Human antimicrobial peptide LL-37 contributes to Alzheimer’s disease progression,” Springer Science and Business Media LLC, Sep. 2022. doi: 10.1038/s41380-022-01790-6. https://doi.org/10.1038/s41380-022-01790-6